Lenalidomide in chronic lymphocytic leukemia: The present and future in the era of tyrosine kinase inhibitors

Critical Reviews in Oncology/Hematology

Volumn 97, Issue , 2016, Pages 291-302

  Maffei, Rossana ^a   Colaci, Elisabetta ^a   Fiorcari, Stefania ^a   Martinelli, Silvia ^a   Potenza, Leonardo ^a   Luppi, Mario ^a   Marasca, Roberto ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Chronic lymphocytic leukemia; Clinical efficacy; Immune activation; Lenalidomide; Microenvironment; Response prediction

Indexed keywords

LENALIDOMIDE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; THALIDOMIDE;

ANEMIA; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PNEUMONIA; PREDICTION; RASH; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEIN KINASE INHIBITORS; THALIDOMIDE;

EID: 84952639130     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.09.003     Document Type: Review

References (97)

1. Acebes-Huerta A., Huergo-Zapico L., Gonzalez-Rodriguez A.P., Fernandez-Guizan A., Payer A.R., Lopez-Soto A., et al. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed. Res. Int. 2014, 2014. 265840.
2. Andritsos L.A., Johnson A.J., Lozanski G., Blum W., Kefauver C., Awan F., et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J. Clin. Oncol. 2008, 26:2519-2525.
3. Audrito V., Serra S., Brusa D., Mazzola F., Arruga F., Vaisitti T., et al. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood 2015, 125:111-123.
4. Aue G., Njuguna N., Tian X., Soto S., Hughes T., Vire B., et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009, 94:1266-1273.
5. Aue G., Nelson L., Lozier J., Tian X., Cullinane A.M., Soto S., Samsel L., et al. Inflammation, TNFalpha and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. Am. J. Hematol. 2011, 86:835-840.
6. Awan F.T., Lapalombella R., Trotta R., Butchar J.P., Yu B., Benson D.M., et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010, 115:1204-1213.
7. Badoux X.C., Keating M.J., Wen S., Lee B.N., Sivina M., Reuben J., et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118:3489-3498.
8. Badoux X.C., Keating M.J., Wen S., Wierda W.G., O'Brien S.M., Faderl S., et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2013, 31:584-591.
9. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25 high regulatory cells in human peripheral blood. J. Immunol. 2001, 167:1245-1253.
10. Bhattacharya N., Diener S., Idler I.S., Rauen J., Habe S., Busch H., et al. Nurse-like cells show deregulated expression of genes involved in immunocompetence. Br. J. Haematol. 2011, 154:349-356.
11. Bjorklund C.C., Ma W., Wang Z.Q., Davis R.E., Kuhn D.J., Kornblau S.M., et al. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J. Biol. Chem. 2011, 286:11009-11020.
12. Bjorklund C.C., Baladandayuthapani V., Lin H.Y., Jones R.J., Kuiatse I., Wang H., et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 2014, 28:373-383.
13. Brown J.R., Abramson J., Hochberg E., Mikler E., Dalton V., Werner L., et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010, 24:1972-1975.
14. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
15. Burger J.A. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr. Hematol. Malig. Rep. 2014, 9:44-49.
16. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2013, 369:32-42.
17. Cantwell M., Hua T., Pappas J., Kipps T.J. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat. Med. 1997, 3:984-989.
18. Chanan-Khan A., Miller K.C., Musial L., Lawrence D., Padmanabhan S., Takeshita K., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J. Clin. Oncol. 2006, 24:5343-5349.
19. Chanan-Khan A., Miller K.C., Lawrence D., Padmanabhan S., Miller A., Hernandez-Illatazurri F., et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011, 117:2127-2135.
20. Chanan-Khan A.A., Chitta K., Ersing N., Paulus A., Masood A., Sher T., et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br. J. Haematol. 2011, 155:457-467.
21. Cheah C.Y., Nastoupil L.J., Neelapu S.S., Forbes S.G., Oki Y., Fowler N.H. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood 2015, 125:3357-3359.
22. Chen C.I., Bergsagel P.L., Paul H., Xu W., Lau A., Dave N., et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J. Clin. Oncol. 2011, 29:1175-1181.
23. Chen C.I., Paul H., Wang T., Le L.W., Dave N., Kukreti V., et al. Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia. Br. J. Haematol. 2014, 165:731-733.
24. Cols M., Barra C.M., He B., Puga I., Xu W., Chiu A., et al. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J. Immunol. 2012, 188:6071-6083.
25. Costa L.J., Fanning S.R., Stephenson J., Afrin L.B., Kistner-Griffin E., Bentz T.A., et al. Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Leuk. Lymphoma 2015, 56:645-649.
26. Cutucache C.E. Tumor-induced host immunosuppression: special focus on CLL. Int. Immunopharmacol. 2013, 17:35-41.
27. D'Arena G., Laurenti L., Minervini M.M., Deaglio S., Bonello L., De Martino L., et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk. Res. 2011, 35:363-368.
28. Desai M., Newberry K., Ou Z., Wang M., Zhang L. Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther. Adv. Hematol. 2014, 5:91-101.
29. Dorfman D.M., Schultze J.L., Shahsafaei A., Michalak S., Gribben J.G., Freeman G.J., et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997, 90:4297-4306.
30. Dubovsky J.A., Beckwith K.A., Natarajan G., Woyach J.A., Jaglowski S., Zhong Y., et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013, 122:2539-2549.
31. Egle A., Steurer M., Gassner F., Geisberger R., Melchardt T., Pleyer L., et al. Lenalidomide/ Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results. Blood 2013, 122:4164.
32. Fecteau J.F., Corral L.G., Ghia E.M., Gaidarova S., Futalan D., Bharati I.S., et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood 2014, 124:1637-1644.
33. Ferrajoli A., Lee B.N., Schlette E.J., O'Brien S.M., Gao H., Wen S., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-5297.
34. Filip A.A., Cisel B., Koczkodaj D., Wasik-Szczepanek E., Piersiak T., Dmoszynska A. Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages?. Blood Cells Mol. Dis. 2013, 50:263-270.
35. Fiorcari S., Martinelli S., Bulgarelli J., Audrito V., Zucchini P., Colaci E., et al. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica 2015, 100:253-262.
36. Flinn I.W., Cooper R.S., Thompson D.S., Waselenko J.K., Reeves J., Wise R.L., et al. Fludarabine, rituximab, and lenalidomide in previously untreated patients with chronic lymphocytic leukemia (CLL): a phase I/II trial of the sarah cannon research institute. Blood 2012, 2012.
37. Fowler N.H., Davis R.E., Rawal S., Nastoupil L., Hagemeister F.B., McLaughlin P., et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014, 15:1311-1318.
38. Gandhi A.K., Kang J., Havens C.G., Conklin T., Ning Y., Wu L., et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br. J. Haematol. 2014, 164:811-821.
39. Gandhi A.K., Mendy D., Waldman M., Chen G., Rychak E., Miller K., et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br. J. Haematol. 2014, 164:233-244.
40. Gassner F.J., Zaborsky N., Neureiter D., Huemer M., Melchardt T., Egle A., et al. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. Haematologica 2014, 99:67-69.
41. Giannoni P., Pietra G., Travaini G., Quarto R., Shyti G., Benelli R., et al. Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica 2014, 99:1078-1087.
42. Gonzalez-Rodriguez A.P., Payer A.R., Acebes-Huerta A., Huergo-Zapico L., Villa-Alvarez M., Gonzalez-Garcia E., et al. Lenalidomide and chronic lymphocytic leukemia. Biomed. Res. Int. 2013, 2013. 932010.
43. Gorgun G., Holderried T.A., Zahrieh D., Neuberg D., Gribben J.G. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J. Clin. Invest. 2005, 115:1797-1805.
44. Gorgun G., Ramsay A.G., Holderried T.A., Zahrieh D., Le Dieu R., Liu F., et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc. Natl. Acad. Sci U. S. A. 2009, 106:6250-6255.
45. Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
46. Hallek M. Chronic lymphocytic leukemia:update on diagnosis, risk stratification and treatment. Am. J. Hematol. 2013, 88:803-816.
47. Heintel D., Rocci A., Ludwig H., Bolomsky A., Caltagirone S., Schreder M., et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br. J. Haematol. 2013, 161:695-700.
48. Herman S.E., Lapalombella R., Gordon A.L., Ramanunni A., Blum K.A., Jones J., et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011, 117:4323-4327.
49. Huergo-Zapico L., Acebes-Huerta A., Gonzalez-Rodriguez A.P., Contesti J., Gonzalez-Garcia E., Payer A.R., et al. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease. PLoS One 2014, 9:e108326.
50. Hus I., Bojarska-Junak A., Chocholska S., Tomczak W., Wos J., Dmoszynska A., et al. Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity. PLoS One 2013, 8:e78091.
51. Idler I., Giannopoulos K., Zenz T., Bhattacharya N., Nothing M., Dohner H., et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br. J. Haematol. 2010, 148:948-950.
52. Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., et al. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327:1345-1350.
53. Jain P., Keating M., Wierda W., Estrov Z., Ferrajoli A., Jain N., et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015, 125:2062-2067.
54. James D.F., Werner L., Brown J.R., Wierda W.G., Barrientos J.C., Castro J.E., et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J. Clin. Oncol. 2014, 32:2067-2073.
55. Jamroziak K., Szemraj J., Robak T., Tukiendorf A., Giannopoulos K. Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen. Leuk. Lymphoma 2015, 56:808-810.
56. Jia L., Clear A., Liu F.T., Matthews J., Uddin N., McCarthy A., et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood 2014, 123:1709-1719.
57. Jonasova A., Bokorova R., Polak J., Vostry M., Kostecka A., Hajkova H., et al. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. Eur. J. Haematol 2015, 95:27-34.
58. Kater A.P., Tonino S.H., Egle A., Ramsay A.G. How does lenalidomide target the chronic lymphocytic leukemia microenvironment?. Blood 2014, 124:2184-2189.
59. Lapalombella R., Yu B., Triantafillou G., Liu Q., Butchar J.P., Lozanski G., et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008, 112:5180-5189.
60. Lapalombella R., Gowda A., Joshi T., Mehter N., Cheney C., Lehman A., et al. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br. J. Haematol. 2009, 144:848-855.
61. Lee B.N., Gao H., Cohen E.N., Badoux X., Wierda W.G., Estrov Z., et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 2011, 117:3999-4008.
62. Lopez-Girona A., Mendy D., Ito T., Miller K., Gandhi A.K., Kang J., et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012, 26:2326-2335.
63. Lopez-Soto A., Folgueras A.R., Seto E., Gonzalez S. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 2009, 28:2370-2382.
64. Maddocks K., Ruppert A.S., Browning R., Jones J., Flynn J., Kefauver C., et al. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leuk. Res. 2014, 38:1025-1029.
65. Maffei R., Martinelli S., Santachiara R., Rossi D., Guarnotta C., Sozzi E., et al. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood 2010, 116:584-592.
66. Maffei R., Fiorcari S., Bulgarelli J., Martinelli S., Castelli I., Deaglio S., et al. Physical contact with endothelial cells through beta1- and beta2-integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. Haematologica 2012, 97:952-960.
67. Maffei R., Fiorcari S., Bulgarelli J., Rizzotto L., Martinelli S., Rigolin G.M., et al. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Exp. Hematol. 2014, 42:126-136.e1. e1.
68. McGraw K.L., Basiorka A.A., Johnson J.O., Clark J., Caceres G., Padron E., et al. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS One 2014, 9:e114249.
69. Moutouh-de Parseval L.A., Weiss L., DeLap R.J., Knight R.D., Zeldis J.B. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J. Clin. Oncol. 2007, 25:5047.
70. Nowakowski G.S., LaPlant B., Macon W.R., Reeder C.B., Foran J.M., Nelson G.D., et al. Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B Cell Phenotype in Newly Diagnosed Diffuse Large B Cell Lymphoma: A Phase II Study. J. Clin. Oncol. 2015, 33:251-257.
71. Pallasch C.P., Hallek M. Incorporating targeted agents into future therapy of chronic lymphocytic leukemia. Semin. Hematol. 2014, 51:235-248.
72. Pellagatti A., Jadersten M., Forsblom A.M., Cattan H., Christensson B., Emanuelsson E.K., et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11406-11411.
73. Pollyea D.A., Coutre S., Gore L., Adler N., Harris P., Phelps M.A., et al. A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood 2014, 124:1987.
74. Ramsay A.G., Johnson A.J., Lee A.M., Gorgun G., Le Dieu R., Blum W., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 2008, 118:2427-2437.
75. Ramsay A.G., Clear A.J., Fatah R., Gribben J.G. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012, 120:1412-1421.
76. Ramsay A.G., Evans R., Kiaii S., Svensson L., Hogg N., Gribben J.G. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013, 121:2704-2714.
77. Riches J.C., Sangaralingam A., Kiaii S., Chaplin T., Cekdemir D., Iqbal S., et al. Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia. Blood 2011, 118:446.
78. Rushworth S.A., Bowles K.M., Barrera L.N., Murray M.Y., Zaitseva L., MacEwan D.J. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal. 2013, 25:106-112.
79. Schulz A., Durr C., Zenz T., Dohner H., Stilgenbauer S., Lichter P., et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. Blood 2013, 121:2503-2511.
80. Shanafelt T.D., Ramsay A.G., Zent C.S., Leis J.F., Tun H.W., Call T.G., et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood 2013, 121:4137-4141.
81. Sher T., Miller K.C., Lawrence D., Whitworth A., Hernandez-Ilizaliturri F., Czuczman M.S., et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk. Lymph. 2010, 51:85-88.
82. Strati P., Keating M.J., Wierda W.G., Badoux X.C., Calin S., Reuben J.M., et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 2013, 122:734-737.
83. Strati P., Keating M.J., Hinojosa C., Faderl S., Smith S.C., O'Brien S., et al. Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia. Blood 2013, 122:4183.
84. Strati P., Keating M.J., O'Brien S.M., Ferrajoli A., Burger J., Faderl S., et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 2014, 99:1350-1355.
85. Troeger A., Johnson A.J., Wood J., Blum W.G., Andritsos L.A., Byrd J.C., et al. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. Blood 2012, 119:4708-4718.
86. Trudel S., Scanga S., Mastronardi F.G., Wei E.N., Mercurio F., Lopez-Girona A., et al. GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL. Blood 2012, 2012.
87. Tsukada N., Burger J.A., Zvaifler N.J., Kipps T.J. Distinctive features of nurselike cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99:1030-1037.
88. Weiss L., Melchardt T., Egle A., Grabmer C., Greil R., Tinhofer I. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011, 117:2163-2169.
89. Woyach J.A., Furman R.R., Liu T.M., Ozer H.G., Zapatka M., Ruppert A.S., et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 2014, 370:2286-2294.
90. Wu L., Adams M., Carter T., Chen R., Muller G., Stirling D., et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin. Cancer Res. 2008, 14:4650-4657.
91. Xia Y., Lu R.N., Li J. Angiogenic factors in chronic lymphocytic leukemia. Leuk. Res. 2012, 36:1211-1217.
92. Yang Y., Shaffer A.L., Emre N.C., Ceribelli M., Zhang M., Wright G., et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012, 21:723-737.
93. Ysebaert L., Fournie J.J. Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia. Leuk. Lymphoma 2011, 52:1404-1406.
94. Zhang L.H., Kosek J., Wang M., Heise C., Schafer P.H., Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br. J. Haematol. 2013, 160:487-502.
95. Zhu Y.X., Braggio E., Shi C.X., Bruins L.A., Schmidt J.E., Van Wiers W., et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011, 118:4771-4779.
96. Zhu Y.X., Kortuem K.M., Stewart A.K. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk. Lymphoma 2013, 54:683-687.
97. Zhu Y.X., Braggio E., Shi C.X., Kortuem K.M., Bruins L.A., Schmidt J.E., et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 2014, 124:536-545.